Drug
Sparc1103 Low Dose
Sparc1103 Low Dose: highest development phase Phase 2, developed by Sun Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sun Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPARC1103 low dose NCT02027025 | Phase 2 | Spasticity |
Latest
No recent events.
Follow Sparc1103 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.